Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients - WMBB News 13 - The Panhandle's News Leader

Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients

  • What's Going Around

  • Wednesday, May 15 2013 11:45 AM EDT2013-05-15 15:45:20 GMT
    While cold and flu season is widely discussed, pneumonia season is quickly gaining the spotlight. One in 20 dies from the lung disease each year, and it's what's going around this week. What is pneumonia? Pneumonia
    While cold and flu season is widely discussed, pneumonia season is quickly gaining the spotlight. One in 20 dies from the lung disease each year, and it's what's going around this week.
  • Wednesday, May 8 2013 9:06 AM EDT2013-05-08 13:06:30 GMT
    We all have our aches in our bellies and backs from time to time, but these pains can also be signs of gallstones. Dr. Hatem Mourad from Coastal Urgent Care and Family Medicine warns that gallstones are
    Dr. Hatem Mourad from Coastal Urgent Care and Family Medicine warns that gallstones are what's going around.

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Amgen

THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program.

As noted by the Government Accountability Office (GAO), it is important that the Centers for Medicare and Medicaid Services (CMS) take the time needed to develop quality metrics and further develop their data systems, both of which are essential to providing quality care for an elderly and chronically ill patient population.

Amgen will continue to advocate for sound federal policies that enhance access to care for these patients.

For more background, please visit Our Perspectives on www.amgen.com.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

©2012 PR Newswire. All Rights Reserved.